Literature DB >> 17017561

Placebo effect and dopamine release.

R de la Fuente-Fernández1, S Lidstone, A J Stoessl.   

Abstract

The placebo effect can be encountered in a great variety of medical conditions, but is particularly prominent in pain, depression and Parkinson's disease. It has been shown that placebo responses play a part in the effect of any type of treatment for Parkinson's disease, including drug therapy, deep brain stimulation and dopamine tissue transplantation. Recent studies have demonstrated that the placebo effect in Parkinson's disease is related to the release of substantial amounts of endogenous dopamine in both the dorsal and ventral striatum. As the ventral striatum is involved in reward processing, these observations suggest that the placebo effect may be linked to reward mechanisms. In keeping with this placebo-reward model, most recent experiments have shown activation of the reward circuitry in association with placebo responses in other disorders. In addition, as dopamine is the major neurotransmitter in the reward circuitry, the model predicts that the release of dopamine in the ventral striatum could be involved in mediating placebo responses not only in Parkinson's but also in other medical conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017561     DOI: 10.1007/978-3-211-45295-0_62

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  11 in total

1.  Placebo response to manual therapy: something out of nothing?

Authors:  Joel E Bialosky; Mark D Bishop; Steven Z George; Michael E Robinson
Journal:  J Man Manip Ther       Date:  2011-02

2.  Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.

Authors:  Jon E Grant; Suck Won Kim; Eric Hollander; Marc N Potenza
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

Review 3.  Behavioural conditioning as the mediator of placebo responses in the immune system.

Authors:  Sabine Vits; Elvir Cesko; Paul Enck; Uwe Hillen; Dirk Schadendorf; Manfred Schedlowski
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

4.  DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study.

Authors:  Weam Fageera; Sarojini M Sengupta; Aurelie Labbe; Natalie Grizenko; Ridha Joober
Journal:  Neuromolecular Med       Date:  2018-07-26       Impact factor: 3.843

5.  Protracted benefit from paradoxical kinesia in typical and atypical parkinsonisms.

Authors:  L Bonanni; A Thomas; F Anzellotti; D Monaco; F Ciccocioppo; S Varanese; S Bifolchetti; M C D'Amico; A Di Iorio; M Onofrj
Journal:  Neurol Sci       Date:  2010-09-22       Impact factor: 3.307

6.  Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.

Authors:  Patricia Di Ciano; Mihail Guranda; Dina Lagzdins; Rachel F Tyndale; Islam Gamaleddin; Peter Selby; Isabelle Boileau; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2015-10-07       Impact factor: 7.853

7.  The mechanisms of manual therapy in the treatment of musculoskeletal pain: a comprehensive model.

Authors:  Joel E Bialosky; Mark D Bishop; Don D Price; Michael E Robinson; Steven Z George
Journal:  Man Ther       Date:  2008-11-21

Review 8.  Placebo, nocebo, and neuropathic pain.

Authors:  Lene Vase; Ina Skyt; Kathryn T Hall
Journal:  Pain       Date:  2016-02       Impact factor: 7.926

Review 9.  Placebo effects in neurological diseases.

Authors:  Alina Dumitriu; Bogdan O Popescu
Journal:  J Med Life       Date:  2010 Apr-Jun

10.  Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial.

Authors:  M Diana van Die; Kerry M Bone; Henry G Burger; Helena J Teede
Journal:  BMC Med Res Methodol       Date:  2009-06-23       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.